Clinical Trial: CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma

Study Status: Terminated
Recruit Status: Unknown status
Study Type: Interventional




Official Title: Study of Cyclophosphamide,Liposome Doxorubicin Dexamethasone(CDD) Plus Bortezomib Compared With CDD in the Relapsed or Refractory Multiple Myeloma Combined With Extramedullary

Brief Summary: The purpose of this study is to determine whether Cyclophosphamide, Liposome doxorubicin and Dexamethasone(CDD) Plus Bortezomib might have effective in extramedullary plasmacytoma.